GJE proud to be ranked consistently at No. 1 by the Financial Times
Posted:
Congratulations to our friends! Gill Jennings & Every LLP is proud to have been recognised with the highest possible rankings by the Financial Times in its 2024 survey of Europe’s leading patent law firms.
Read more here.
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers. …
Wearable technology that monitors our bodies can be helpful and harmful.
Wearable technology affords the opportunity to check, re-check, and check again, leading to fixation.
Read the full article in the Psychology Today blog post here.